Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 621

1.

Resistance against Integrase Strand Transfer Inhibitors and Relevance to HIV Persistence.

Mesplède T, Wainberg MA.

Viruses. 2015 Jul 7;7(7):3703-18. doi: 10.3390/v7072790. Review.

2.

Identification of a dibenzocyclooctadiene lignan as a HIV-1 non-nucleoside reverse transcriptase inhibitor.

Han YS, Xiao WL, Xu H, Kramer VG, Quan Y, Mesplède T, Oliveira M, Colby-Germinario SP, Sun HD, Wainberg MA.

Antivir Chem Chemother. 2015 Feb;24(1):28-38. doi: 10.1177/2040206614566580.

PMID:
26149264
3.

Dolutegravir maintains a durable effect against HIV replication in tissue culture even after drug washout.

Osman N, Mesplède T, Quashie PK, Oliveira M, Zanichelli V, Wainberg MA.

J Antimicrob Chemother. 2015 Jul 4. pii: dkv176. [Epub ahead of print]

PMID:
26142476
4.

Structural Studies of the HIV-1 Integrase Protein: Compound Screening and Characterization of a DNA-Binding Inhibitor.

Quashie PK, Han YS, Hassounah S, Mesplède T, Wainberg MA.

PLoS One. 2015 Jun 5;10(6):e0128310. doi: 10.1371/journal.pone.0128310. eCollection 2015.

5.

HIV-1 group O resistance against integrase inhibitors.

Depatureaux A, Mesplède T, Quashie P, Oliveira M, Moisi D, Plantier JC, Brenner B, Wainberg MA.

J Acquir Immune Defic Syndr. 2015 May 21. [Epub ahead of print]

PMID:
26017662
6.

A resveratrol analog termed 3,3',4,4',5,5'-hexahydroxy-trans-stilbene is a potent HIV-1 inhibitor.

Han YS, Quashie PK, Mesplède T, Xu H, Quan Y, Jaeger W, Szekeres T, Wainberg MA.

J Med Virol. 2015 May 18. doi: 10.1002/jmv.24271. [Epub ahead of print]

PMID:
25989218
7.

Will drug resistance against dolutegravir in initial therapy ever occur?

Wainberg MA, Han YS.

Front Pharmacol. 2015 Apr 29;6:90. doi: 10.3389/fphar.2015.00090. eCollection 2015. Review.

8.

Limonoids with Anti-HIV Activity from Cipadessa cinerascens.

Yu JH, Wang GC, Han YS, Wu Y, Wainberg MA, Yue JM.

J Nat Prod. 2015 Jun 26;78(6):1243-52. doi: 10.1021/acs.jnatprod.5b00025. Epub 2015 May 13.

PMID:
25970729
9.

Long lasting control of viral rebound with a new drug ABX464 targeting Rev - mediated viral RNA biogenesis.

Campos N, Myburgh R, Garcel A, Vautrin A, Lapasset L, Nadal ES, Mahuteau-Betzer F, Najman R, Fornarelli P, Tantale K, Basyuk E, Séveno M, Venables JP, Pau B, Bertrand E, Wainberg MA, Speck RF, Scherrer D, Tazi J.

Retrovirology. 2015 Apr 9;12:30. doi: 10.1186/s12977-015-0159-3.

10.

Dolutegravir inhibits HIV-1 Env evolution in primary human cells.

Mesplède T, Moïsi D, Oliveira M, Ibanescu I, Ohnona F, Brenner B, Wainberg MA.

AIDS. 2015 Mar 27;29(6):659-65. doi: 10.1097/QAD.0000000000000606.

PMID:
25849829
11.

The CRISPR/Cas9 system inactivates latent HIV-1 proviral DNA.

Zhu W, Lei R, Le Duff Y, Li J, Guo F, Wainberg MA, Liang C.

Retrovirology. 2015 Feb 27;12:22. doi: 10.1186/s12977-015-0150-z.

12.

Subtype-specific analysis of the K65R substitution in HIV-1 that confers hypersusceptibility to a novel nucleotide-competing reverse transcriptase inhibitor.

Xu HT, Colby-Germinario SP, Quashie PK, Bethell R, Wainberg MA.

Antimicrob Agents Chemother. 2015 Jun;59(6):3189-96. doi: 10.1128/AAC.00315-15. Epub 2015 Mar 16.

PMID:
25779585
13.

Editorial Commentary: Clinical Significance of HIV Subtype Variability in Regard to Treatment Outcome.

Wainberg MA.

Clin Infect Dis. 2015 May 15;60(10):1550-1. doi: 10.1093/cid/civ107. Epub 2015 Feb 13. No abstract available.

PMID:
25681379
14.

Combination of the R263K and M184I/V resistance substitutions against dolutegravir and lamivudine decreases HIV replicative capacity.

Singhroy DN, Wainberg MA, Mesplède T.

Antimicrob Agents Chemother. 2015 May;59(5):2882-5. doi: 10.1128/AAC.05181-14. Epub 2015 Feb 9.

PMID:
25666155
15.

Dolutegravir resistance mutation R263K cannot coexist in combination with many classical integrase inhibitor resistance substitutions.

Anstett K, Mesplede T, Oliveira M, Cutillas V, Wainberg MA.

J Virol. 2015 Apr;89(8):4681-4. doi: 10.1128/JVI.03485-14. Epub 2015 Feb 4.

PMID:
25653436
16.

Simian-tropic HIV as a model to study drug resistance against integrase inhibitors.

Wares M, Hassounah S, Mesplède T, Sandstrom PA, Wainberg MA.

Antimicrob Agents Chemother. 2015 Apr;59(4):1942-9. doi: 10.1128/AAC.04829-14. Epub 2015 Jan 12.

PMID:
25583721
17.

Differential effects of the G118R, H51Y, and E138K resistance substitutions in different subtypes of HIV integrase.

Quashie PK, Oliviera M, Veres T, Osman N, Han YS, Hassounah S, Lie Y, Huang W, Mesplède T, Wainberg MA.

J Virol. 2015 Mar;89(6):3163-75. doi: 10.1128/JVI.03353-14. Epub 2014 Dec 31.

PMID:
25552724
18.

How will the ebola crisis impact the HIV epidemic?

Wainberg MA, Lever AM.

Retrovirology. 2014 Nov 30;11:110. doi: 10.1186/s12977-014-0110-z. No abstract available.

19.

HIV and Ebola: similarities and differences.

Wainberg MA, Kippax S, Bras M, Sow PS.

J Int AIDS Soc. 2014 Dec 1;17:19896. doi: 10.7448/IAS.17.1.19896. eCollection 2014. No abstract available.

20.

The dual CCR5 and CCR2 inhibitor cenicriviroc does not redistribute HIV into extracellular space: implications for plasma viral load and intracellular DNA decline.

Kramer VG, Hassounah S, Colby-Germinario SP, Oliveira M, Lefebvre E, Mesplède T, Wainberg MA.

J Antimicrob Chemother. 2015 Mar;70(3):750-6. doi: 10.1093/jac/dku451. Epub 2014 Nov 27.

PMID:
25433008
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk